The Rising Participation of Market Players and Increasing Prevalence of Cancer Boost the Global Active Pharmaceutical Ingredient for Cancer Market

Pune, India, August 2019 /MRFR Press Release/- Market Research Future published a Half-Cooked Research Report on the Global Active Pharmaceutical Ingredient (API) for Cancer Market.

Market Highlights

The Global Active Pharmaceutical Ingredient (API) for Cancer Market is expected to grow significantly over the forecast period. The API for cancer market held a valuation of USD 19,500.00 million in 2018 and is projected to register a CAGR of 8.1% over the forecast period.

The increasing participation of key players is one of the key factors driving the API for cancer market. For instance, various cancer drugs manufacturers such as Johnson & Johnson received US Food and Drug Administration approval for product Balversa (erdafitinib), oral fibroblast growth factor receptor (FGFR) kinase inhibitor in April 2019.

Various other factors that are driving the API for cancer market are rising FDA approvals of anticancer drugs, growing demand for newly developed small molecules drugs.

However, the side-effects of chemotherapy may hamper market growth over the forecast period.

Segmentation

The global API for cancer market is segmented based on product, type, indications, end users, and region.

Based on type, API for cancer market is segmented into Tinib, Parib, rafenib, Lisib, Degib, Ciclib, and others

Based on the indication, the market is segmented into blood cancer, skin cancer, lungs cancer, breasts cancer, pancreas cancer, others. Anti-cancer drugs are available in the market to treat various types of cancer. The chemotherapy is preferred for treatment. As per the report World Health organization in 2018 among the types of cancer lung cancer is responsible for the largest number of deaths about 1.8 million deaths which is 18.4% of the total number of prevalence worldwide. Thus, the lung cancer segments have higher growth compared to the other indications in this segment. Based on end user, the market is segmented into pharmaceutical companies, research organizations, others. Pharmaceutical companies’ major consumer of API for cancer. There is larger number of manufacturers producing anti-cancer products. The API has compounded the excipients into the desired dosage forms. The pharmaceutical companies segment holds the major share in this segment as it deals with a larger number of pharmaceutical companies compared to research organizations.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/active-pharmaceutical-ingredient-for-cancer-market-8300

Regional Analysis

In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The global API for cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European global API for cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The API for cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The global Myelodysplastic Syndrome drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players

Various players operate in the global API for cancer market such as AbbVie, Pfizer Inc, Boehringer Ingelheim International GmbH, AstraZeneca, Novartis AG., F. Hoffmann-La Roche AG, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd, Johnson & Johnson, Merck & Co. Inc., Amgen Inc., and others.